Researchers outlined both clinical obstacles for T‑cell receptor (TCR) therapies in ovarian cancer and new insights into VEGF‑driven vascular pathways that fuel tumor growth. The TCR review cataloged current technical, antigen‑targeting, and tumor‑microenvironment challenges limiting durable responses, while complementary vascular studies identified actionable nodes in the VEGF axis that support angiogenesis and metastasis. Together, the reports recommend integrated strategies combining adoptive T‑cell modalities with agents that normalize tumor vasculature or modulate immune infiltration. Sponsors and investigators are considering combination trials to test whether vascular modulation can enhance T‑cell trafficking and therapeutic efficacy.